Baillie Gifford & CO 2seventy Bio, Inc. Call Options Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TSVT
# of Institutions
126Shares Held
45.6MCall Options Held
122KPut Options Held
19.8K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$23.6 Million2.31% of portfolio
-
Goldman Sachs Group Inc New York, NY4.22MShares$16.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.77MShares$14.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$14.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.89MShares$11.5 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $150M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...